Nikozipix (Cytisinicline)

Cytisinicline binds partially to α4β2 nicotinic acetylcholine receptors in the brain. This partial activation eases withdrawal while blocking nicotine’s full stimulatory effect, thereby lowering the urge to smoke.

The dosage of Nikozipix is determined by the prescribing healthcare professional based on individual patient needs and local regulatory guidance. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for cytisinicline in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against unknown risks and discuss options with pregnant or nursing patients.

To request Nikozipix, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common alternative is varenicline, another nicotinic receptor partial agonist. Both target the same receptor subtype, but cytisinicline may have a different side‑effect profile and dosing schedule. Choice of therapy depends on individual tolerance, contraindications and clinician judgment.

Nikozipix should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use after the expiry date.

Nikozipix is taken orally, typically as a tablet. The exact administration schedule—such as timing relative to meals—should follow the prescriber’s directions. Swallow the tablet whole with water unless instructed otherwise.

Serious adverse events, though rare, include mood alterations such as depression or suicidal thoughts, severe allergic reactions (anaphylaxis), cardiovascular effects like hypertension or tachycardia, and seizures. Patients should seek immediate medical attention if any of these occur.

Nikozipix is contraindicated in individuals with known hypersensitivity to cytisinicline or any excipients, patients with uncontrolled severe cardiovascular disease, and those taking monoamine oxidase inhibitors. Pregnant or breastfeeding women should only use it after a risk‑benefit assessment by their clinician.